Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference being held from November 10-12, 2025 in Boston.

Details of the event are as follows:

Date: Tuesday, November 11, 2025

Time: 3:00 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  208.32
+0.40 (0.19%)
AAPL  267.90
-5.05 (-1.85%)
AMD  199.34
-4.34 (-2.13%)
BAC  49.38
-2.92 (-5.59%)
GOOG  307.75
+0.60 (0.20%)
META  643.87
-13.14 (-2.00%)
MSFT  395.22
-6.50 (-1.62%)
NVDA  179.85
-5.04 (-2.73%)
ORCL  144.42
-5.89 (-3.92%)
TSLA  401.33
-7.25 (-1.77%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.